New hope in battle against deadly pancreatic cancer
NCT ID NCT07076212
Summary
This study is testing which of two chemotherapy combinations works better for people with advanced pancreatic cancer that hasn't been treated before. Researchers will compare NALIRIFOX (a newer combination) against mGAP (a modified version of three existing drugs) in 52 patients. The main goal is to see which treatment shrinks tumors more effectively while monitoring side effects and survival.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Medical University of South Carolina Hollings Cancer Center
RECRUITINGCharleston, South Carolina, 29425, United States
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.